By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: Foundayo is a new once-daily weight-loss pill that works through the same GLP-1 pathway as Wegovy and Ozempic, but it's built from an entirely different type of molecule — one that doesn't require fasting or special timing to work. In trials, it produced meaningful weight loss, though somewhat less than the strongest injectable options.
If you've come across the name Foundayo and aren't sure how it fits alongside Wegovy, Zepbound, or the other GLP-1 medications you've heard of, here's what it actually is, how it's different at a chemical level, and what the trial data shows.
Foundayo is the brand name for orforglipron, a medication developed by Eli Lilly. Like Wegovy and Ozempic, it activates the GLP-1 receptor — the same hormone pathway responsible for reducing appetite, slowing digestion, and helping regulate blood sugar. Where it differs is in what kind of molecule it is.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are both peptides — essentially short chains of amino acids engineered to mimic natural gut hormones. Orforglipron is not a peptide at all. It's a small-molecule drug, chemically closer to a conventional pill medication like ibuprofen or a statin than to an injectable peptide hormone.
Peptides are fragile. They get broken down by stomach acid and digestive enzymes almost immediately, which is why semaglutide was only available as an injection for years, and why the oral version that eventually launched (the Wegovy pill) needs a special absorption-enhancing ingredient and strict fasting rules to work at all.
Small molecules like orforglipron don't have this problem. They're naturally more resistant to digestion and can be absorbed through the intestinal lining without any special workaround. That's the direct reason Foundayo can be taken once daily with no fasting, no water restrictions, and no waiting period before eating — a real practical difference from oral semaglutide, not just a marketing distinction.
Foundayo was approved by the FDA in 2026 under the agency's National Priority Voucher program. Its approved use is for reduction and long-term maintenance of excess body weight in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity.
As of this initial approval, Foundayo is positioned specifically as a weight-management medication. A type 2 diabetes indication is being studied separately and is not yet part of the current label — so if you're looking at Foundayo for diabetes rather than weight management, that's not what it's currently approved for.
The medication is taken once daily as an oral tablet, with the dose gradually increased over time based on how well someone tolerates it — similar in concept to how other GLP-1 medications are titrated, just on a daily rather than weekly schedule.
Foundayo's approval was based on the ATTAIN series of phase 3 trials. In ATTAIN-1, which followed roughly 3,127 adults with obesity or overweight (without diabetes) for 72 weeks, the highest studied dose (36 mg daily) produced an average weight loss of about 12.4% of starting body weight, compared to roughly 0.9% in the placebo group. Across the range of doses studied in various trials, results generally fell between 6% and 12% weight loss, alongside improvements in blood sugar markers, cholesterol, and blood pressure.
Lined up against the major trials for other GLP-1 medications:
| Medication | Trial | Duration | Avg Weight Loss |
|---|---|---|---|
| Foundayo (orforglipron), 36 mg | ATTAIN-1 | 72 weeks | ~12.4% |
| Oral semaglutide 25 mg (Wegovy pill) | OASIS-4 | 64 weeks | ~13.6% |
| Injectable semaglutide 2.4 mg (Wegovy) | STEP-1 | 68 weeks | ~14.9% |
| Injectable tirzepatide, up to 15 mg (Zepbound) | SURMOUNT-1 | 72 weeks | Up to 20.9% |
Foundayo's results land at the more modest end of the current GLP-1 landscape — meaningfully better than placebo, but behind both injectable semaglutide and the high-dose oral Wegovy pill, and further behind tirzepatide, which remains the strongest performer across trials due to its dual-receptor mechanism.
An indirect comparison specifically pitting oral semaglutide (OASIS-4) against orforglipron (ATTAIN-1) found oral semaglutide associated with about 3 percentage points more weight loss, along with fewer people stopping treatment due to side effects. That said, one exception is worth noting: in a head-to-head trial (ACHIEVE-3) that compared orforglipron directly against standard-dose oral semaglutide — not the higher 25 mg dose used for weight management, but the lower doses typically used for diabetes — orforglipron outperformed on both blood sugar control and weight loss. So the comparison isn't uniformly in one direction; it depends specifically on which dose of oral semaglutide is being compared against.
Foundayo's side effect profile follows the same pattern as every other GLP-1 medication: nausea, constipation, diarrhea, vomiting, and abdominal discomfort are the most commonly reported effects, generally mild to moderate in severity. These gastrointestinal symptoms were also the leading reason participants discontinued treatment in trials — consistent with what's seen across the entire GLP-1 drug class, regardless of whether the medication is a pill or an injection.
Since both are pills, this is probably the most relevant comparison for anyone specifically trying to avoid injections.
Oral semaglutide (Wegovy pill, Rybelsus) requires a co-formulated absorption enhancer to survive digestion, and that comes with real constraints: taken on an empty stomach, with only a small amount of plain water, and a mandatory 30-minute wait before eating or taking other medications.
Foundayohas none of these restrictions. It's taken once daily without regard to meals or timing.
The tradeoff is in the numbers: oral semaglutide's trial results were somewhat better than Foundayo's at their respective top doses. So the practical choice comes down to a real tradeoff — Foundayo offers meaningfully more convenience day-to-day, while oral semaglutide has shown somewhat stronger average results at its highest studied dose.
Eli Lilly is continuing to study orforglipron for additional uses, including type 2 diabetes — early trial data has shown improvements in blood sugar control alongside weight loss. There's also ongoing research into whether people who've already lost weight on an injectable medication like tirzepatide can maintain that weight loss after switching to Foundayo, which would be a meaningful option for someone who wants to eventually move off injections without losing progress. None of this pipeline work has resulted in expanded FDA approvals yet — it's worth watching, not yet available.
Q: Is Foundayo the same thing as Ozempic or Wegovy?
No. All three work through the GLP-1 receptor, but Foundayo (orforglipron) is a completely different type of molecule — a small molecule rather than a peptide — which is why it doesn't need the injection or the fasting rules that come with semaglutide-based medications.
Q: Does Foundayo require fasting like the Wegovy pill does?
No — this is one of its main advantages. Foundayo can be taken once daily without food or water restrictions, unlike oral semaglutide.
Q: Is Foundayo as effective as Wegovy or Zepbound?
Not quite, based on current trial data. Its top-dose results (~12.4% average weight loss) were somewhat lower than injectable semaglutide (~14.9%) and notably lower than injectable tirzepatide (up to 20.9%). It's still a clinically meaningful result, just not the strongest option currently available.
Q: Can Foundayo be used for type 2 diabetes?
Not yet — its current FDA approval is specifically for weight management. Diabetes-focused trials are ongoing but haven't resulted in an expanded approval as of this writing.
Q: Is Foundayo available as an injection too?
No, Foundayo is only available as an oral tablet. There's no injectable version of orforglipron.
See also: Oral vs. Injectable GLP-1 for a side-by-side comparison of all current options including Foundayo, and What Is a GLP-1 Medication? for a plain-language explanation of how the entire drug class works.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizOral GLP-1 pills have closed much of the gap with weekly injections. Here's how the two approaches compare on results, convenience, and what the trial data actually shows.
GLP-1 medications explained in plain language: what they are, how they work in your gut and brain, and what the research shows about weight loss results.
Tirzepatide activates one more hormone receptor than semaglutide — and across every major trial, that difference shows up as more average weight loss.